文献速递帕金森病与运动障碍

β2肾上腺素能受体药物与帕金森病风险

β2-adrenoreceptor medications and risk of Parkinson disease.
PubMed 文献 · Ann Neurol · 2018-10-30

基于2009年美国联邦医疗保险受益人大型人群病例对照研究(48,295例新发帕金森病与52,324例对照),调整临床适应症与用药滞后后,普萘洛尔与帕金森病风险的关联消失,非震颤适应症的β拮抗剂似乎降低风险,β2激动剂沙丁胺醇与吸入糖皮质激素未显示一致关联;结论认为β2肾上腺素能受体激动剂与拮抗剂似乎不改变帕金森病风险。

要点

  • 调整震颤等适应症及用药滞后后,普萘洛尔与帕金森病风险关联为0.97(95%CI 0.80-1.18),不再显著。
  • 非震颤适应症的β拮抗剂似乎降低帕金森病风险:卡维地洛OR=0.77(95%CI 0.73-0.81),美托洛尔OR=0.94(95%CI 0.91-0.97)。
  • 沙丁胺醇与吸入糖皮质激素均未显示与帕金森病风险的一致关联。

核心结论

  • β2肾上腺素能受体激动剂与拮抗剂似乎不改变帕金森病风险。

研究设计与样本

  • 大型人群病例对照研究,纳入2009年美国联邦医疗保险受益人,含诊断码、操作码与处方数据,共48,295例新发帕金森病病例和52,324例对照。

主要发现

  • 普萘洛尔似乎增加帕金森病风险(OR=3.62,95%CI 3.31-3.96);调整帕金森病诊断/参照日期前的震颤或不自主运动并滞后普萘洛尔暴露后,关联为0.97(95%CI 0.80-1.18)。
  • 同样用于震颤的扑米酮对该调整与滞后同样敏感。
  • 非震颤适应症的β拮抗剂似乎降低帕金森病风险:卡维地洛OR=0.77(95%CI 0.73-0.81),美托洛尔OR=0.94(95%CI 0.91-0.97),且对适应症调整与滞后不敏感。
  • 沙丁胺醇与吸入糖皮质激素均未与帕金森病风险呈一致关联。

关键数值与推荐

  • 普萘洛尔初始OR=3.62(95%CI 3.31-3.96),经震颤/不自主运动调整与用药滞后后OR=0.97(95%CI 0.80-1.18)。
  • 卡维地洛OR=0.77(95%CI 0.73-0.81);美托洛尔OR=0.94(95%CI 0.91-0.97)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A recent study observed a 2-fold greater risk of Parkinson disease (PD) in relation to the β2-adrenoreceptor antagonist propranolol and a markedly lower risk of PD for the β2-adrenoreceptor agonist salbutamol. We examined whether confounding by clinical indication for these medications, that is, tremor and smoking-related pulmonary conditions, explained these associations. METHODS: In a large, population-based case-control study of United States Medicare beneficiaries in 2009 with diagnosis codes, procedure codes, and prescription data (48,295 incident PD cases, 52,324 controls), we examined the risk of PD in relation to use of selected β antagonists (propranolol, carvedilol, metoprolol), the β2 agonist salbutamol, and other medications used for the same clinical indications (primidone, inhaled corticosteroids). We adjusted for demographics, smoking, and overall use of medical care. We then examined the effect of also adjusting for clinical indication and applying medication exposure lagging. RESULTS: Propranolol appeared to increase PD risk (odds ratio [OR] = 3.62, 95% confidence interval [CI] = 3.31-3.96). When we adjusted for tremor or abnormal involuntary movement prior to the PD diagnosis/reference date and lagged propranolol exposure, the association was 0.97 (95% CI = 0.80-1.18). Primidone, also used for tremor, was similarly sensitive to this adjustment and lagging. β Antagonists not indicated for tremor appeared to reduce PD risk (carvedilol: OR = 0.77, 95% CI = 0.73-0.81; metoprolol: OR = 0.94, 95% CI = 0.91-0.97) and were insensitive to adjustment for indications and lagging. Neither salbutamol nor inhaled corticosteroids were consistently associated with PD risk. INTERPRETATION: β2-adrenoreceptor agonists and antagonists do not appear to alter PD risk. Ann Neurol 2018;84:691-701.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Searles Nielsen S, Gross A, Camacho-Soto A, et al. β2-adrenoreceptor medications and risk of Parkinson disease. Ann Neurol. 2018. PMID: 30225948. doi:10.1002/ana.25341

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。